Concerns on the dosing of antitubercular drugs for children in RNTCP

Indian Pediatrics

Volumn 45, Issue 10, 2008, Pages 852-854

  Lodha, Rakesh ^a   Menon, P Ramesh ^a   Kabra, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Children; RNTCP; Treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; BODY WEIGHT; CHILD HEALTH CARE; DRUG DOSE REGIMEN; DRUG FORMULATION; HEALTH PROGRAM; HUMAN; RECOMMENDED DRUG DOSE; RISK MANAGEMENT; TUBERCULOSIS; TUBERCULOSIS CONTROL; WEIGHT CHANGE; WEIGHT GAIN;

ANTITUBERCULAR AGENTS; BODY WEIGHT; CLINICAL PROTOCOLS; COMMUNICABLE DISEASE CONTROL; HUMANS; INDIA; NATIONAL HEALTH PROGRAMS; TUBERCULOSIS;

EID: 55849150198     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. RNTCP Status Report. TB India 2007. Central TB Division, DGHS, MoHFW. New Delhi: Government of India; 2007. p. 40- 42.
2. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-1374.
3. Joint Tuberculosis Committee of BTS. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
4. nd Edition. Geneva: WHO/HTM/TB/ 2004.329. p. 112.
5. nd Edition. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 759-771.
6. Dickinson JM, Mitchison DA. In vitro studies on the choice of drugs for intermittent chemotherapy of tuberculosis. Tubercle 1966; 47: 370-380.
7. Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979; 119: 879-894.
8. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-279.
9. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. Common errors and their association with the acquisition of drug resistance. JAMA 1993; 270: 65-68.
10. Kucers A. Isoniazid. In: Kucers A, Crowe SM, Grayson ML, et al. The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 5th ed. Boston: Butterworth-Heinemann; 1997. p. 1179-1210.
11. Abate G, Hoffner SE, Thomsen VO, Miorner H. Characterization of isoniazid-resistant strains of Mycobacterium tuberculosis on the basis of phenotypic properties and mutations in katG. Eur J Clin Microbiol Infect Dis 2001; 20: 329-333.
12. Lewis ML. Antibacterial agents: ethambutol. In: Yu VL, Merigan TC, Barriere SL, eds. Antimicrobial Therapy and Vaccines. Baltimore: Williams & Wilkins; 1999. p. 643-650.
13. Heifets LB, Iseman MD, Lindholm-Levy PJ. Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuber-culosis. Antimicrob Agents Chemother 1986; 30: 927-932.
14. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis:the results up to 24 months. Tubercle 1979; 60: 201-210.
15. Chan ED, Chatterjee D, Iseman MD, Heifets LB. Pyrazinamide, ethambutol, ethionamide, and aminoglycosides. In, Rom WN, Garay SM (Eds). Tuberculosis. 2nd Edition. Philadelphia: Lippincott Williams & Wilkins. 2004. p. 773-789.